Can We Use a Lower Dose of Liposomal Amphotericin B for the Treatment of Mucosal American Leishmaniasis?

Valdir Sabbaga Amato, Felipe Francisco Tuon, Raphael A. Camargo, Regina Maia de Souza, Carolina Rocio Oliveira Santos, Antônio Carlos Nicodemo

American Journal of Tropical Medicine and Hygiene · 2011 · 32 citations · 9 references

DOIFull text

Open access

Concepts

Abstract

Liposomal amphotericin B has been used as an alternative treatment of mucosal leishmaniasis, but the optimal dose is not established. We retrospectively reviewed the clinical outcome of eight patients with mucosal leishmaniasis treated with liposomal amphotericin B. The mean total dose was 35 mg/kg (range 24-50 mg/kg), which resulted in the healing of all the lesions in all patients and no recurrences were observed during the follow-up period (mean 25 months; range 7-40 months).

References

9